Avexitide for low blood sugar after weight-loss surgery
Part of Hormones & metabolism clinical trials.
This expanded access program provides avexitide, an investigational drug for low blood sugar after weight-loss surgery, to people who either finished the LUCIDITY trial on this drug or took part in earlier avexitide studies for this condition. It aims to offer continued treatment when no other satisfactory options are available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and able to understand and sign a consent form.
- You cannot get avexitide through a regular clinical trial or other satisfactory treatment.
- If you are a woman who could become pregnant, you must use highly effective birth control and have a negative pregnancy test before starting. No breastfeeding or nursing.
- If you are a man, you must agree to use highly effective birth control during the program.
- You must have finished the LUCIDITY trial on avexitide (Category A) OR have been in a previous avexitide study for low blood sugar after gastric bypass, or tried to join LUCIDITY but couldn't because it was full (Category B).
- You must not be using medicines like Byetta, Victoza, Ozempic, or Mounjaro (GLP-1 drugs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who recently stopped taking a GLP-1 medication (like Wegovy or Ozempic) to understand how weight, eating habits, and daily routines change over time. It aims to help patients and doctors know what to expect after stopping the drug.
This study tests a medication called mizagliflozin to help people who have low blood sugar after gastric bypass surgery. It may reduce the number of low blood sugar episodes and improve symptoms.
This trial tests whether a diabetes medication called dapagliflozin helps smooth out blood sugar swings after bariatric (weight-loss) surgery. It may help people with type 2 diabetes achieve better control after their surgery.
This trial tests whether canakinumab can reduce frequent low blood sugar episodes after bariatric (weight-loss) surgery. It is designed for people who keep having low blood sugar despite dietary changes.
This study looks at how the hormone glucagon affects blood sugar in people who have had gastric bypass or sleeve gastrectomy surgery more than a year ago, compared to people who have not had any gastrointestinal surgery. It aims to understand glucose metabolism better and may help improve care for people after bariatric surgery.
This early study looks at a gut hormone–based treatment (GLP-1) and how it affects blood sugar and digestion after gastric bypass. It may help people who are having repeated low blood sugar episodes after surgery.
Hear when a new Post-bariatric Hypoglycemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.